MARCO and hepatocellular carcinoma: Additionally, several studies in hepatocellular carcinoma, liver metastases of CRC and NSCLC have detected a similar cluster of TAMs evolving from RTMs with high expression of scavenger receptor MARCO [15, 16, 184], and anti-MARCO treatment was shown to synergize with anti-CTLA4 checkpoint inhibition in the B16 model and MC38 colon cancer mouse model [185].